The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinical trials. However, the dose intensity of conventional chemotherapy has been pushed to its limit. Further improvement in outcome will need to rely more heavily on molecular therapeutic as well as immuno- and cellular-therapy approaches together with precise risk stratification. Children with ETV6-RUNX1 or hyperdiploid>50 ALL who achieve negative minimal residual disease during early remission induction are suitable candidates for reduction in treatment. Patients with Philadelphia chromosome (Ph)-positive or Ph-like ALL with ABL-class fusion should be treated with dasatinib. BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell precursor, immature T-cell, KMT2A-rearranged, Ph-positive and TCF-HLF-positive ALL, that may respond to BCL-2 inhibitor venetoclax. There are other fusions or mutations that may serve as putative targets, but effective targeted therapy has yet to be established. For other high-risk patients or poor early treatment responders who do not have targetable genetic lesions, current approaches that offer hope include blinatumomab, inotuzumab and CAR-T cell therapy for B-ALL, and daratumumab and nelarabine for T-ALL. With the expanding therapeutic armamentarium, we should start focus on rational combinations of targeted therapy with non-overlapping toxicities.
A Möricke, M Zimmermann, MG Valsecchi, M Stanulla, A Biondi, G Mann, F Locatelli, G Cazzaniga, F Niggli, M Aricò, CR Bartram, A Attarbaschi, D Silvestri, R Beier, G Basso, R Ratei, AE Kulozik, L Lo Nigro, B Kremens, J Greiner, R Parasole, J Harbott, R Caruso, A von Stackelberg, E Barisone, C Rössig, V Conter, M Schrappe. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127(17): 2101–2112 https://doi.org/10.1182/blood-2015-09-670729
pmid: 26888258
2
G Escherich, M Zimmermann, , CoALL study group Janka-Schaub. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03. Pediatr Blood Cancer 2013; 60(2): 254–257 https://doi.org/10.1002/pbc.24273
pmid: 22948968
3
SP Hunger, X Lu, M Devidas, BM Camitta, PS Gaynon, NJ Winick, GH Reaman, WL Carroll. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012; 30(14): 1663–1669 https://doi.org/10.1200/JCO.2011.37.8018
pmid: 22412151
4
R Pieters, H de Groot-Kruseman, V Van der Velden, M Fiocco, H van den Berg, E de Bont, RM Egeler, P Hoogerbrugge, G Kaspers, E Van der Schoot, V De Haas, J Van Dongen. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 2016; 34(22): 2591–2601 https://doi.org/10.1200/JCO.2015.64.6364
pmid: 27269950
5
LM Vrooman, TM Blonquist, MH Harris, KE Stevenson, AE Place, SK Hunt, JE O’Brien, BL Asselin, UH Athale, LA Clavell, PD Cole, KM Kelly, C Laverdiere, JM Leclerc, B Michon, MA Schorin, ML Sulis, JJG Welch, DS Neuberg, SE Sallan, LB Silverman. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv 2018; 2(12): 1449–1458 https://doi.org/10.1182/bloodadvances.2018016584
pmid: 29941458
6
C Domenech, S Suciu, B De Moerloose, F Mazingue, G Plat, A Ferster, A Uyttebroeck, N Sirvent, P Lutz, K Yakouben, M Munzer, P Röhrlich, D Plantaz, F Millot, P Philippet, N Dastugue, S Girard, H Cavé, Y Benoit, Y Bertrandfor, Children's Leukemia Group (CLG) of European Organisation for Research and Treatment of Cancer (EORTC). Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99(7): 1220–1227 https://doi.org/10.3324/haematol.2014.103507
pmid: 24727815
7
A Vora, N Goulden, C Mitchell, J Hancock, R Hough, C Rowntree, AV Moorman, R Wade. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 2014; 15(8): 809–818 https://doi.org/10.1016/S1470-2045(14)70243-8
pmid: 24924991
8
N Toft, H Birgens, J Abrahamsson, L Griškevičius, H Hallböök, M Heyman, TW Klausen, ÓG Jónsson, K Palk, K Pruunsild, P Quist-Paulsen, G Vaitkeviciene, K Vettenranta, A Åsberg, TL Frandsen, HV Marquart, HO Madsen, U Norén-Nyström, K Schmiegelow. Results of NOPHO ALL2008 treatment for patients aged 1−45 years with acute lymphoblastic leukemia. Leukemia 2018; 32(3): 606–615 https://doi.org/10.1038/leu.2017.265
pmid: 28819280
9
S Jeha, D Pei, J Choi, C Cheng, JT Sandlund, E Coustan-Smith, D Campana, H Inaba, JE Rubnitz, RC Ribeiro, TA Gruber, SC Raimondi, RB Khan, JJ Yang, CG Mullighan, JR Downing, WE Evans, MV Relling, CH Pui. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol 2019; 37(35): 3377–3391 https://doi.org/10.1200/JCO.19.01692
pmid: 31657981
10
HC Liu, TC Yeh, JY Hou, KH Chen, TH Huang, CY Chang, DC Liang. Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. J Clin Oncol 2014; 32(17): 1825–1829 https://doi.org/10.1200/JCO.2013.54.5020
pmid: 24821882
11
CH Pui, D Campana, D Pei, WP Bowman, JT Sandlund, SC Kaste, RC Ribeiro, JE Rubnitz, SC Raimondi, M Onciu, E Coustan-Smith, LE Kun, S Jeha, C Cheng, SC Howard, V Simmons, A Bayles, ML Metzger, JM Boyett, W Leung, R Handgretinger, JR Downing, WE Evans, MV Relling. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360(26): 2730–2741 https://doi.org/10.1056/NEJMoa0900386
pmid: 19553647
12
DT Teachey, CH Pui. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019; 20(3): e142–e154 https://doi.org/10.1016/S1470-2045(19)30031-2
pmid: 30842058
13
Z Gu, ML Churchman, KG Roberts, I Moore, X Zhou, J Nakitandwe, K Hagiwara, S Pelletier, S Gingras, H Berns, D Payne-Turner, A Hill, I Iacobucci, L Shi, S Pounds, C Cheng, D Pei, C Qu, S Newman, M Devidas, Y Dai, SC Reshmi, J Gastier-Foster, EA Raetz, MJ Borowitz, BL Wood, WL Carroll, PA Zweidler-McKay, KR Rabin, LA Mattano, KW Maloney, A Rambaldi, O Spinelli, JP Radich, MD Minden, JM Rowe, S Luger, MR Litzow, MS Tallman, J Racevskis, Y Zhang, R Bhatia, J Kohlschmidt, K Mrózek, CD Bloomfield, W Stock, S Kornblau, HM Kantarjian, M Konopleva, WE Evans, S Jeha, CH Pui, J Yang, E Paietta, JR Downing, MV Relling, J Zhang, ML Loh, SP Hunger, CG Mullighan. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet 2019; 51(2): 296–307 https://doi.org/10.1038/s41588-018-0315-5
pmid: 30643249
14
YF Liu, BY Wang, WN Zhang, JY Huang, BS Li, M Zhang, L Jiang, JF Li, MJ Wang, YJ Dai, ZG Zhang, Q Wang, J Kong, B Chen, YM Zhu, XQ Weng, ZX Shen, JM Li, J Wang, XJ Yan, Y Li, YM Liang, L Liu, XQ Chen, WG Zhang, JS Yan, JD Hu, SH Shen, J Chen, LJ Gu, D Pei, Y Li, G Wu, X Zhou, RB Ren, C Cheng, JJ Yang, KK Wang, SY Wang, J Zhang, JQ Mi, CH Pui, JY Tang, Z Chen, SJ Chen. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine 2016; 8: 173–183 https://doi.org/10.1016/j.ebiom.2016.04.038
pmid: 27428428
15
Y Liu, J Easton, Y Shao, J Maciaszek, Z Wang, MR Wilkinson, K McCastlain, M Edmonson, SB Pounds, L Shi, X Zhou, X Ma, E Sioson, Y Li, M Rusch, P Gupta, D Pei, C Cheng, MA Smith, JG Auvil, DS Gerhard, MV Relling, NJ Winick, AJ Carroll, NA Heerema, E Raetz, M Devidas, CL Willman, RC Harvey, WL Carroll, KP Dunsmore, SS Winter, BL Wood, BP Sorrentino, JR Downing, ML Loh, SP Hunger, J Zhang, CG Mullighan. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 2017; 49(8): 1211–1218 https://doi.org/10.1038/ng.3909
pmid: 28671688
16
CH Pui, KE Nichols, JJ Yang. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 2019; 16(4): 227–240 https://doi.org/10.1038/s41571-018-0136-6
pmid: 30546053
17
M Schrappe, K Bleckmann, M Zimmermann, A Biondi, A Möricke, F Locatelli, G Cario, C Rizzari, A Attarbaschi, MG Valsecchi, CR Bartram, E Barisone, F Niggli, C Niemeyer, AM Testi, G Mann, O Ziino, B Schäfer, R Panzer-Grümayer, R Beier, R Parasole, G Göhring, WD Ludwig, F Casale, PG Schlegel, G Basso, V Conter. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol 2018; 36(3): 244–253 https://doi.org/10.1200/JCO.2017.74.4946
pmid: 29148893
18
CH Pui, D Pei, SC Raimondi, E Coustan-Smith, S Jeha, C Cheng, WP Bowman, JT Sandlund, RC Ribeiro, JE Rubnitz, H Inaba, TA Gruber, WH Leung, JJ Yang, JR Downing, WE Evans, MV Relling, D Campana. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia 2017; 31(2): 333–339 https://doi.org/10.1038/leu.2016.234
pmid: 27560110
19
B Wood, D Wu, B Crossley, Y Dai, D Williamson, C Gawad, MJ Borowitz, M Devidas, KW Maloney, E Larsen, N Winick, E Raetz, WL Carroll, SP Hunger, ML Loh, H Robins, I Kirsch. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 2018; 131(12): 1350–1359 https://doi.org/10.1182/blood-2017-09-806521
pmid: 29284596
20
J Zhang, K McCastlain, H Yoshihara, B Xu, Y Chang, ML Churchman, G Wu, Y Li, L Wei, I Iacobucci, Y Liu, C Qu, J Wen, M Edmonson, D Payne-Turner, KB Kaufmann, SI Takayanagi, E Wienholds, E Waanders, P Ntziachristos, S Bakogianni, J Wang, I Aifantis, KG Roberts, J Ma, G Song, J Easton, HL Mulder, X Chen, S Newman, X Ma, M Rusch, P Gupta, K Boggs, B Vadodaria, J Dalton, Y Liu, ML Valentine, L Ding, C Lu, RS Fulton, L Fulton, Y Tabib, K Ochoa, M Devidas, D Pei, C Cheng, J Yang, WE Evans, MV Relling, CH Pui, S Jeha, RC Harvey, IL Chen, CL Willman, G Marcucci, CD Bloomfield, J Kohlschmidt, K Mrózek, E Paietta, MS Tallman, W Stock, MC Foster, J Racevskis, JM Rowe, S Luger, SM Kornblau, SA Shurtleff, SC Raimondi, ER Mardis, RK Wilson, JE Dick, SP Hunger, ML Loh, JR Downing, CG, Mullighan St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 2016; 48(12): 1481–1489 https://doi.org/10.1038/ng.3691
pmid: 27776115
21
H Lilljebjörn, R Henningsson, A Hyrenius-Wittsten, L Olsson, C Orsmark-Pietras, S von Palffy, M Askmyr, M Rissler, M Schrappe, G Cario, A Castor, CJ Pronk, M Behrendtz, F Mitelman, B Johansson, K Paulsson, AK Andersson, M Fontes, T Fioretos. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia. Nat Commun 2016; 7(1): 11790 https://doi.org/10.1038/ncomms11790
pmid: 27265895
22
SS Winter, KP Dunsmore, M Devidas, BL Wood, N Esiashvili, Z Chen, N Eisenberg, N Briegel, RJ Hayashi, JM Gastier-Foster, AJ Carroll, NA Heerema, BL Asselin, PS Gaynon, MJ Borowitz, ML Loh, KR Rabin, EA Raetz, PA Zweidler-Mckay, NJ Winick, WL Carroll, SP Hunger. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol 2018; 36(29): 2926–2934 https://doi.org/10.1200/JCO.2018.77.7250
pmid: 30138085
23
KR Schultz, A Carroll, NA Heerema, WP Bowman, A Aledo, WB Slayton, H Sather, M Devidas, HW Zheng, SM Davies, PS Gaynon, M Trigg, R Rutledge, D Jorstad, N Winick, MJ Borowitz, SP Hunger, WL Carroll, B, Children’s Oncology Group Camitta. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia 2014; 28(7): 1467–1471 https://doi.org/10.1038/leu.2014.30
pmid: 24441288
24
A Biondi, M Schrappe, P De Lorenzo, A Castor, G Lucchini, V Gandemer, R Pieters, J Stary, G Escherich, M Campbell, CK Li, A Vora, M Aricò, S Röttgers, V Saha, MG Valsecchi. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13(9): 936–945 https://doi.org/10.1016/S1470-2045(12)70377-7
pmid: 22898679
25
A Biondi, V Gandemer, P De Lorenzo, G Cario, M Campbell, A Castor, R Pieters, A Baruchel, A Vora, V Leoni, J Stary, G Escherich, CK Li, G Cazzaniga, H Cavé, J Bradtke, V Conter, V Saha, M Schrappe, M Grazia Valsecchi. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol 2018; 5(12): e641–e652 https://doi.org/10.1016/S2352-3026(18)30173-X
pmid: 30501871
26
NJ Short, H Kantarjian, CH Pui, A Goldstone, E Jabbour. SOHO State of the Art Update and Next Questions: Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2018; 18(7): 439–446 https://doi.org/10.1016/j.clml.2018.05.015
pmid: 29853276
27
K Porkka, P Koskenvesa, T Lundán, J Rimpiläinen, S Mustjoki, R Smykla, R Wild, R Luo, M Arnan, B Brethon, L Eccersley, H Hjorth-Hansen, M Höglund, H Klamova, H Knutsen, S Parikh, E Raffoux, F Gruber, F Brito-Babapulle, H Dombret, RF Duarte, E Elonen, R Paquette, CM Zwaan, FY Lee. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112(4): 1005–1012 https://doi.org/10.1182/blood-2008-02-140665
pmid: 18477770
28
WB Slayton, KR Schultz, JA Kairalla, M Devidas, X Mi, MA Pulsipher, BH Chang, C Mullighan, I Iacobucci, LB Silverman, MJ Borowitz, AJ Carroll, NA Heerema, JM Gastier-Foster, BL Wood, SL Mizrahy, T Merchant, VI Brown, L Sieger, MJ Siegel, EA Raetz, NJ Winick, ML Loh, WL Carroll, SP Hunger. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of Children’s Oncology Group Trial AALL0622. J Clin Oncol 2018; 36(22): 2306–2314 https://doi.org/10.1200/JCO.2017.76.7228
pmid: 29812996
29
SP Hunger, V Saha, M Devidas, et al.. CA180–372: An international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2017; 130(Suppl 1): 98
30
S Shen, X Chen, J Cai, J Yu, J Gao, S Hu, X Zhai, C Liang, X Ju, H Jiang, R Jin, X Wu, N Wang, X Tian, K Pan, H Jiang, L Sun, Y Fang, CK Li, Q Hu, M Yang, Y Zhu, H Zhang, C Li, D Pei, S Jeha, JJ Yang, C Cheng, J Tang, X Zhu, CH Pui. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol 2020; 6(3): 358–366 https://doi.org/10.1001/jamaoncol.2019.5868
31
E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, M Konopleva, N Pemmaraju, W Wierda, G Garcia-Manero, K Sasaki, J Cortes, R Garris, JD Khoury, J Jorgensen, N Jain, J Alvarez, S O’Brien, H Kantarjian. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 2018; 5(12): e618–e627 https://doi.org/10.1016/S2352-3026(18)30176-5
pmid: 30501869
KG Roberts, SC Reshmi, RC Harvey, IM Chen, K Patel, E Stonerock, H Jenkins, Y Dai, M Valentine, Z Gu, Y Zhao, J Zhang, D Payne-Turner, M Devidas, NA Heerema, AJ Carroll, EA Raetz, MJ Borowitz, BL Wood, LA Mattano Jr, KW Maloney, WL Carroll, ML Loh, CL Willman, JM Gastier-Foster, CG Mullighan, SP Hunger. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group. Blood 2018; 132(8): 815–824 https://doi.org/10.1182/blood-2018-04-841676
pmid: 29997224
34
JM Boer, EM Steeghs, JR Marchante, A Boeree, JJ Beaudoin, HB Beverloo, RP Kuiper, G Escherich, VH van der Velden, CE van der Schoot, HA de Groot-Kruseman, R Pieters, ML den Boer. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget 2017; 8(3): 4618–4628 https://doi.org/10.18632/oncotarget.13492
pmid: 27894077
35
SK Tasian, SP Hunger. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. Br J Haematol 2017; 176(6): 867–882 https://doi.org/10.1111/bjh.14474
pmid: 27984637
36
KG Roberts, D Pei, D Campana, D Payne-Turner, Y Li, C Cheng, JT Sandlund, S Jeha, J Easton, J Becksfort, J Zhang, E Coustan-Smith, SC Raimondi, WH Leung, MV Relling, WE Evans, JR Downing, CG Mullighan, CH Pui. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014; 32(27): 3012–3020 https://doi.org/10.1200/JCO.2014.55.4105
pmid: 25049327
37
L Holmfeldt, L Wei, E Diaz-Flores, M Walsh, J Zhang, L Ding, D Payne-Turner, M Churchman, A Andersson, SC Chen, K McCastlain, J Becksfort, J Ma, G Wu, SN Patel, SL Heatley, LA Phillips, G Song, J Easton, M Parker, X Chen, M Rusch, K Boggs, B Vadodaria, E Hedlund, C Drenberg, S Baker, D Pei, C Cheng, R Huether, C Lu, RS Fulton, LL Fulton, Y Tabib, DJ Dooling, K Ochoa, M Minden, ID Lewis, LB To, P Marlton, AW Roberts, G Raca, W Stock, G Neale, HG Drexler, RA Dickins, DW Ellison, SA Shurtleff, CH Pui, RC Ribeiro, M Devidas, AJ Carroll, NA Heerema, B Wood, MJ Borowitz, JM Gastier-Foster, SC Raimondi, ER Mardis, RK Wilson, JR Downing, SP Hunger, ML Loh, CG Mullighan. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45(3): 242–252 https://doi.org/10.1038/ng.2532
pmid: 23334668
38
M Qian, X Cao, M Devidas, W Yang, C Cheng, Y Dai, A Carroll, NA Heerema, H Zhang, T Moriyama, JM Gastier-Foster, H Xu, E Raetz, E Larsen, N Winick, WP Bowman, PL Martin, ER Mardis, R Fulton, G Zambetti, M Borowitz, B Wood, KE Nichols, WL Carroll, CH Pui, CG Mullighan, WE Evans, SP Hunger, MV Relling, ML Loh, JJ Yang. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol 2018; 36(6): 591–599 https://doi.org/10.1200/JCO.2017.75.5215
pmid: 29300620
CH Pui, P Rebora, M Schrappe, A Attarbaschi, A Baruchel, G Basso, H Cavé, S Elitzur, K Koh, HC Liu, K Paulsson, R Pieters, LB Silverman, J Stary, A Vora, A Yeoh, CJ Harrison, MG, Ponte di Legno Childhood ALL Working Group Valsecchi. Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study. J Clin Oncol 2019; 37(10): 770–779 https://doi.org/10.1200/JCO.18.00822
pmid: 30657737
41
JL McNeer, M Devidas, Y Dai, AJ Carroll, NA Heerema, JM Gastier-Foster, SB Kahwash, MJ Borowitz, BL Wood, E Larsen, KW Maloney, L Mattano, NJ Winick, KR Schultz, SP Hunger, WL Carroll, ML Loh, EA Raetz. Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from Children’s Oncology Group. J Clin Oncol 2019; 37(10): 780–789 https://doi.org/10.1200/JCO.18.00884
pmid: 30742559
42
E Diaz-Flores, EQ Comeaux, KL Kim, E Melnik, K Beckman, KL Davis, K Wu, J Akutagawa, O Bridges, R Marino, M Wohlfeil, BS Braun, CG Mullighan, ML Loh. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res 2019; 79(9): 2339–2351 https://doi.org/10.1158/0008-5472.CAN-18-0236
pmid: 30862722
43
F Seyfried, S Demir, RL Hörl, FU Stirnweiß, J Ryan, A Scheffold, M Villalobos-Ortiz, E Boldrin, J Zinngrebe, S Enzenmüller, S Jenni, YC Tsai, B Bornhauser, A Fürstberger, JM Kraus, HA Kestler, JP Bourquin, S Stilgenbauer, A Letai, KM Debatin, LH Meyer. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis 2019; 10(8): 571 https://doi.org/10.1038/s41419-019-1801-0
pmid: 31358732
44
TN Chonghaile, JE Roderick, C Glenfield, J Ryan, SE Sallan, LB Silverman, ML Loh, SP Hunger, B Wood, DJ DeAngelo, R Stone, M Harris, A Gutierrez, MA Kelliher, A Letai. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 2014; 4(9): 1074–1087 https://doi.org/10.1158/2159-8290.CD-14-0353
pmid: 24994123
45
S Peirs, F Matthijssens, S Goossens, I Van de Walle, K Ruggero, CE de Bock, S Degryse, K Canté-Barrett, D Briot, E Clappier, T Lammens, B De Moerloose, Y Benoit, B Poppe, JP Meijerink, J Cools, J Soulier, TH Rabbitts, T Taghon, F Speleman, P Van Vlierberghe. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014; 124(25): 3738–3747 https://doi.org/10.1182/blood-2014-05-574566
pmid: 25301704
46
SL Khaw, S Suryani, K Evans, J Richmond, A Robbins, RT Kurmasheva, CA Billups, SW Erickson, Y Guo, PJ Houghton, MA Smith, H Carol, AW Roberts, DC Huang, RB Lock. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood 2016; 128(10): 1382–1395 https://doi.org/10.1182/blood-2016-03-707414
pmid: 27343252
47
JM Benito, L Godfrey, K Kojima, L Hogdal, M Wunderlich, H Geng, I Marzo, KG Harutyunyan, L Golfman, P North, J Kerry, E Ballabio, TN Chonghaile, O Gonzalo, Y Qiu, I Jeremias, L Debose, E O’Brien, H Ma, P Zhou, R Jacamo, E Park, KR Coombes, N Zhang, DA Thomas, S O’Brien, HM Kantarjian, JD Leverson, SM Kornblau, M Andreeff, M Müschen, PA Zweidler-McKay, JC Mulloy, A Letai, TA Milne, M Konopleva. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Reports 2015; 13(12): 2715–2727 https://doi.org/10.1016/j.celrep.2015.12.003
pmid: 26711339
48
M Scherr, A Elder, K Battmer, D Barzan, S Bomken, M Ricke-Hoch, A Schröder, L Venturini, HJ Blair, J Vormoor, O Ottmann, A Ganser, A Pich, D Hilfiker-Kleiner, O Heidenreich, M Eder. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 2014; 28(3): 554–565 https://doi.org/10.1038/leu.2013.361
pmid: 24280866
49
JT Leonard, JS Rowley, CA Eide, E Traer, B Hayes-Lattin, M Loriaux, SE Spurgeon, BJ Druker, JW Tyner, BH Chang. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med 2016; 8(354): 354ra114 https://doi.org/10.1126/scitranslmed.aaf5309
pmid: 27582059
50
U Fischer, M Forster, A Rinaldi, T Risch, S Sungalee, HJ Warnatz, B Bornhauser, M Gombert, C Kratsch, AM Stütz, M Sultan, J Tchinda, CL Worth, V Amstislavskiy, N Badarinarayan, A Baruchel, T Bartram, G Basso, C Canpolat, G Cario, H Cavé, D Dakaj, M Delorenzi, MP Dobay, C Eckert, E Ellinghaus, S Eugster, V Frismantas, S Ginzel, OA Haas, O Heidenreich, G Hemmrich-Stanisak, K Hezaveh, JI Höll, S Hornhardt, P Husemann, P Kachroo, CP Kratz, G Te Kronnie, B Marovca, F Niggli, AC McHardy, AV Moorman, R Panzer-Grümayer, BS Petersen, B Raeder, M Ralser, P Rosenstiel, D Schäfer, M Schrappe, S Schreiber, M Schütte, B Stade, R Thiele, N von der Weid, A Vora, M Zaliova, L Zhang, T Zichner, M Zimmermann, H Lehrach, A Borkhardt, JP Bourquin, A Franke, JO Korbel, M Stanulla, ML Yaspo. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015; 47(9): 1020–1029 https://doi.org/10.1038/ng.3362
pmid: 26214592
51
Z Gu, M Churchman, K Roberts, Y Li, Y Liu, RC Harvey, K McCastlain, SC Reshmi, D Payne-Turner, I Iacobucci, Y Shao, IM Chen, M Valentine, D Pei, KL Mungall, AJ Mungall, Y Ma, R Moore, M Marra, E Stonerock, JM Gastier-Foster, M Devidas, Y Dai, B Wood, M Borowitz, EE Larsen, K Maloney, LA Mattano Jr, A Angiolillo, WL Salzer, MJ Burke, F Gianni, O Spinelli, JP Radich, MD Minden, AV Moorman, B Patel, AK Fielding, JM Rowe, SM Luger, R Bhatia, I Aldoss, SJ Forman, J Kohlschmidt, K Mrózek, G Marcucci, CD Bloomfield, W Stock, S Kornblau, HM Kantarjian, M Konopleva, E Paietta, CL Willman, ML Loh, SP Hunger, CG Mullighan. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 2016; 7: 13331 https://doi.org/10.1038/ncomms13331
pmid: 27824051
52
T Yasuda, S Tsuzuki, M Kawazu, F Hayakawa, S Kojima, T Ueno, N Imoto, S Kohsaka, A Kunita, K Doi, T Sakura, T Yujiri, E Kondo, K Fujimaki, Y Ueda, Y Aoyama, S Ohtake, J Takita, E Sai, M Taniwaki, M Kurokawa, S Morishita, M Fukayama, H Kiyoi, Y Miyazaki, T Naoe, H Mano. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet 2016; 48(5): 569–574 https://doi.org/10.1038/ng.3535
pmid: 27019113
53
K Suzuki, Y Okuno, N Kawashima, H Muramatsu, T Okuno, X Wang, S Kataoka, Y Sekiya, M Hamada, N Murakami, D Kojima, K Narita, A Narita, H Sakaguchi, K Sakaguchi, N Yoshida, N Nishio, A Hama, Y Takahashi, K Kudo, K Kato, S Kojima. MEF2D-BCL9 fusion gene is associated with high-risk acute B-cell precursor lymphoblastic leukemia in adolescents. J Clin Oncol 2016; 34(28): 3451–3459 https://doi.org/10.1200/JCO.2016.66.5547
pmid: 27507882
54
JF Li, YT Dai, H Lilljebjörn, SH Shen, BW Cui, L Bai, YF Liu, MX Qian, Y Kubota, H Kiyoi, I Matsumura, Y Miyazaki, L Olsson, AM Tan, H Ariffin, J Chen, J Takita, T Yasuda, H Mano, B Johansson, JJ Yang, AE Yeoh, F Hayakawa, Z Chen, CH Pui, T Fioretos, SJ Chen, JY Huang. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA 2018; 115(50): E11711–E11720 https://doi.org/10.1073/pnas.1814397115
pmid: 30487223
55
TB Alexander, Z Gu, I Iacobucci, K Dickerson, JK Choi, B Xu, D Payne-Turner, H Yoshihara, ML Loh, J Horan, B Buldini, G Basso, S Elitzur, V de Haas, CM Zwaan, A Yeoh, D Reinhardt, D Tomizawa, N Kiyokawa, T Lammens, B De Moerloose, D Catchpoole, H Hori, A Moorman, AS Moore, O Hrusak, S Meshinchi, E Orgel, M Devidas, M Borowitz, B Wood, NA Heerema, A Carrol, YL Yang, MA Smith, TM Davidsen, LC Hermida, P Gesuwan, MA Marra, Y Ma, AJ Mungall, RA Moore, SJM Jones, M Valentine, LJ Janke, JE Rubnitz, CH Pui, L Ding, Y Liu, J Zhang, KE Nichols, JR Downing, X Cao, L Shi, S Pounds, S Newman, D Pei, JM Guidry Auvil, DS Gerhard, SP Hunger, H Inaba, CG Mullighan. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 2018; 562(7727): 373–379 https://doi.org/10.1038/s41586-018-0436-0
pmid: 30209392
56
O Hrusak, V de Haas, J Stancikova, B Vakrmanova, I Janotova, E Mejstrikova, V Capek, J Trka, M Zaliova, A Luks, K Bleckmann, A Möricke, J Irving, B Konatkowska, TB Alexander, H Inaba, K Schmiegelow, S Stokley, Z Zemanova, AV Moorman, JG Rossi, MS Felice, L Dalla-Pozza, J Morales, M Dworzak, B Buldini, G Basso, M Campbell, ME Cabrera, N Marinov, S Elitzur, S Izraeli, D Luria, T Feuerstein, A Kolenova, P Svec, O Kreminska, KR Rabin, S Polychronopoulou, E da Costa, HV Marquart, A Kattamis, R Ratei, D Reinhardt, JK Choi, M Schrappe, J Stary. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood 2018; 132(3): 264–276 https://doi.org/10.1182/blood-2017-12-821363
pmid: 29720486
57
CJ Harrison, AV Moorman, C Schwab, AJ Carroll, EA Raetz, M Devidas, S Strehl, K Nebral, J Harbott, A Teigler-Schlegel, M Zimmerman, N Dastuge, A Baruchel, J Soulier, MF Auclerc, A Attarbaschi, G Mann, B Stark, G Cazzaniga, L Chilton, P Vandenberghe, E Forestier, I Haltrich, SC Raimondi, M Parihar, JP Bourquin, J Tchinda, C Haferlach, A Vora, SP Hunger, NA Heerema, OA, Haas Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2014; 28(5): 1015–1021 https://doi.org/10.1038/leu.2013.317
pmid: 24166298
58
H Rafei, HM Kantarjian, EJ Jabbour. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol 2020; 188(2): 207–223 https://doi.org/10.1111/bjh.16207
pmid: 31566728
59
R Assi, H Kantarjian, NJ Short, N Daver, K Takahashi, G Garcia-Manero, C DiNardo, J Burger, J Cortes, N Jain, W Wierda, S Chamoun, M Konopleva, E Jabbour. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 2017; 17(12): 897–901 https://doi.org/10.1016/j.clml.2017.08.101
pmid: 28927784
60
A von Stackelberg, F Locatelli, G Zugmaier, R Handgretinger, TM Trippett, C Rizzari, P Bader, MM O’Brien, B Brethon, D Bhojwani, PG Schlegel, A Borkhardt, SR Rheingold, TM Cooper, CM Zwaan, P Barnette, C Messina, G Michel, SG DuBois, K Hu, M Zhu, JA Whitlock, L Gore. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 2016; 34(36): 4381–4389 https://doi.org/10.1200/JCO.2016.67.3301
pmid: 27998223
61
G Martinelli, N Boissel, P Chevallier, O Ottmann, N Gökbuget, MS Topp, AK Fielding, A Rambaldi, EK Ritchie, C Papayannidis, LR Sterling, J Benjamin, A Stein. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 2017; 35(16): 1795–1802 https://doi.org/10.1200/JCO.2016.69.3531
pmid: 28355115
62
HM Kantarjian, DJ DeAngelo, M Stelljes, G Martinelli, M Liedtke, W Stock, N Gökbuget, S O'Brien, K Wang, T Wang, ML Paccagnella, B Sleight, E Vandendries, AS Advani. Inotuzumabozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016; 375(8): 740–753 https://doi.org/10.1056/NEJMoa1509277
pmid: 27292104
63
D Bhojwani, R Sposto, NN Shah, V Rodriguez, C Yuan, M Stetler-Stevenson, MM O’Brien, JL McNeer, A Quereshi, A Cabannes, P Schlegel, C Rossig, L Dalla-Pozza, K August, S Alexander, JP Bourquin, M Zwaan, EA Raetz, ML Loh, SR Rheingold. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia 2019; 33(4): 884–892 https://doi.org/10.1038/s41375-018-0265-z
pmid: 30267011
64
E Jabbour, K Sasaki, F Ravandi, X Huang, NJ Short, M Khouri, P Kebriaei, J Burger, J Khoury, J Jorgensen, N Jain, M Konopleva, G Garcia-Manero, T Kadia, J Cortes, J Jacob, K Montalbano, R Garris, S O’Brien, HM Kantarjian. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 2018; 124(20): 4044–4055 https://doi.org/10.1002/cncr.31720
pmid: 30307611
65
SL Maude, TW Laetsch, J Buechner, S Rives, M Boyer, H Bittencourt, P Bader, MR Verneris, HE Stefanski, GD Myers, M Qayed, B De Moerloose, H Hiramatsu, K Schlis, KL Davis, PL Martin, ER Nemecek, GA Yanik, C Peters, A Baruchel, N Boissel, F Mechinaud, A Balduzzi, J Krueger, CH June, BL Levine, P Wood, T Taran, M Leung, KT Mueller, Y Zhang, K Sen, D Lebwohl, MA Pulsipher, SA Grupp. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378(5): 439–448 https://doi.org/10.1056/NEJMoa1709866
pmid: 29385370
66
SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, DT Teachey, A Chew, B Hauck, JF Wright, MC Milone, BL Levine, CH June. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368(16): 1509–1518 https://doi.org/10.1056/NEJMoa1215134
pmid: 23527958
67
X Chen, Y Wang, M Ruan, J Li, M Zhong, Z Li, F Liu, S Wang, Y Chen, L Liu, JJ Yang, X Zhu, J Wang, CH Pui. Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells. Clin Lymphoma Myeloma Leuk 2020; 20(6): 366–370 https://doi.org/10.1016/j.clml.2019.10.016
68
TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, S Ramakrishna, P Wolters, S Martin, C Delbrook, B Yates, H Shalabi, TJ Fountaine, JF Shern, RG Majzner, DF Stroncek, M Sabatino, Y Feng, DS Dimitrov, L Zhang, S Nguyen, H Qin, B Dropulic, DW Lee, CL Mackall. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24(1): 20–28 https://doi.org/10.1038/nm.4441
pmid: 29155426
69
H Qin, S Ramakrishna, S Nguyen, TJ Fountaine, A Ponduri, M Stetler-Stevenson, CM Yuan, W Haso, JF Shern, NN Shah, TJ Fry. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics 2018; 11: 127–137 https://doi.org/10.1016/j.omto.2018.10.006
pmid: 30581986
70
D Gomes-Silva, M Srinivasan, S Sharma, CM Lee, DL Wagner, TH Davis, RH Rouce, G Bao, MK Brenner, M Mamonkin. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017; 130(3): 285–296 https://doi.org/10.1182/blood-2017-01-761320
pmid: 28539325
71
YT Png, N Vinanica, T Kamiya, N Shimasaki, E Coustan-Smith, D Campana. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv 2017; 1(25): 2348–2360 https://doi.org/10.1182/bloodadvances.2017009928
pmid: 29296885
72
M Mamonkin, RH Rouce, H Tashiro, MK Brenner. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 2015; 126(8): 983–992 https://doi.org/10.1182/blood-2015-02-629527
pmid: 26056165
73
D Sánchez-Martínez, ML Baroni, F Gutierrez-Agüera, H Roca-Ho, O Blanch-Lombarte, S González-García, M Torrebadell, J Junca, M Ramírez-Orellana , T Velasco-Hernández, C Bueno, JL Fuster, JG Prado, J Calvo, B Uzan, J Cools, M Camos, F Pflumio, ML Toribio, P Menéndez. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 2019; 133(21): 2291–2304 https://doi.org/10.1182/blood-2018-10-882944
pmid: 30796021
74
ML Cooper, J Choi, K Staser, JK Ritchey, JM Devenport, K Eckardt, MP Rettig, B Wang, LG Eissenberg, A Ghobadi, LN Gehrs, JL Prior, S Achilefu, CA Miller, CC Fronick, J O’Neal, F Gao, DM Weinstock, A Gutierrez, RS Fulton, JF DiPersio. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 2018; 32(9): 1970–1983 https://doi.org/10.1038/s41375-018-0065-5
pmid: 29483708
75
J Rasaiyaah, C Georgiadis, R Preece, U Mock, W Qasim. TCRab/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight 2018; 3(13): 99442 https://doi.org/10.1172/jci.insight.99442
pmid: 29997304
76
KP Dunsmore, S Winter, M Devidas, BL Wood, N Esiashvili, N Eisenberg, N Briegel, RJ Hayashi, JM Gastier-Foster, AJ Carroll, NA Heerema, B Asselin, KR Rabin, P Zweidler-McKay, EA Raetz, ML Loh, NJ Winick, WL Carroll, S Hunger. Nikki Briegel, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin B, Rabin KR, Zweidler-McKay P, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger S. COG AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy. J Clin Oncol 2018; 36(suppl 15): 10500 https://doi.org/10.1200/JCO.2018.36.15_suppl.10500
77
KL Bride, TL Vincent, SY Im, R Aplenc, DM Barrett, WL Carroll, R Carson, Y Dai, M Devidas, KP Dunsmore, T Fuller, T Glisovic-Aplenc, TM Horton, SP Hunger, ML Loh, SL Maude, EA Raetz, SS Winter, SA Grupp, ML Hermiston, BL Wood, DT Teachey. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood 2018; 131(9): 995–999 https://doi.org/10.1182/blood-2017-07-794214
pmid: 29305553
78
AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen, BD Dayton, H Ding, SH Enschede, WJ Fairbrother, DC Huang, SG Hymowitz, S Jin, SL Khaw, PJ Kovar, LT Lam, J Lee, HL Maecker, KC Marsh, KD Mason, MJ Mitten, PM Nimmer, A Oleksijew, CH Park, CM Park, DC Phillips, AW Roberts, D Sampath, JF Seymour, ML Smith, GM Sullivan, SK Tahir, C Tse, MD Wendt, Y Xiao, JC Xue, H Zhang, RA Humerickhouse, SH Rosenberg, SW Elmore. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19(2): 202–208 https://doi.org/10.1038/nm.3048
pmid: 23291630
